Comparing the current results to its competitors, Biocryst Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2026 by 33.61 % year on year. The sales growth was above Biocryst Pharmaceuticals Inc 's competitors' average revenue growth of 11.4 %, achieved in the same quarter.
Biocryst Pharmaceuticals Inc Net Income in the 2 quarter 2026 grew year on year by 1441.69%, while most of its competitors have experienced a net loss.
July 9, 2024
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 In a significant development for patients suffering from hereditary angioedema (HAE), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has approved ORLADEYO (berotralstat). The approval is for oral, once-daily use of berotralstat for the prophylaxis of HAE attacks in adults and pediatric patients aged 12 years and older. A Landmark Approval with Global ImplicationsThe approval in Peru signifies a noteworthy expansion for BioCryst Pharmaceuticals, cementing its commitment to providing innovative treatments on a global scale. HAE, characterized by recurrent episodes of sev...
June 2, 2024
BioCryst Pharmaceuticals, Inc. has recently presented new real-world evidence on the use of ORLADEYO (berotralstat), an oral, once-daily treatment for hereditary angioedema (HAE) patients in the United States. The findings demonstrate significant reductions in healthcare resource utilization (HRU) after starting ORLADEYO therapy.HAE is a rare genetic disorder characterized by recurrent episodes of swelling in various body parts, such as the hands, feet, face, and airways. These attacks can be debilitating and potentially life-threatening if not promptly treated. Traditionally, attenuated androgens have been used as a prophylactic treatment for HAE, but they come with various tolerability issues and long-term...
May 9, 2024
BioCryst s ORLADEYO Shows Promising Reductions in Healthcare Resource Utilization for Patients with HAE: A Breakthrough in HAE Treatment Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of swelling in various body parts, including the face, limbs, genitals, and gastrointestinal tract. These episodes can be painful, disfiguring, and potentially life-threatening if not properly managed. However, BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) brings new hope to HAE patients with their oral medication ORLADEYO (berotralstat). In a recent study, BioCryst revealed compelling real-world evidence that demonstrates the significant reduction in healthcare resource utilization (...
February 19, 2024
In recent news, BioCryst Pharmaceuticals, Inc. has made significant strides in improving the treatment options available for patients with hereditary angioedema (HAE) and has also unveiled promising developments in its pipeline. This article discusses the recent launch of ORLADEYO (berotralstat) in Italy as a breakthrough oral therapy for the prevention of recurrent HAE attacks, as well as the updates shared during BioCryst s RandD Day, highlighting their commitment to advancing first-in-class and best-in-class therapies.ORLADEYO: A Revolutionary Therapy for HAE Patients in ItalyBioCryst Pharmaceuticals, Inc. has achieved a major milestone in the field of HAE treatment with the approval and reimbursement rec...
Publicly Traded Peers of Biocryst Pharmaceuticals Inc
Vertex Pharmaceuticals Inc Share Performance
+15.26%
This Year
Vertex Pharmaceuticals Inc
Profile
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Incyte Corporation is a biopharmaceutical company that primarily focuses on the research, development, and commercialization of innovative medicines targeting oncology and serious inflammatory conditions. Their business model emphasizes robust R&D investments to discover potential drug candidates, often engaging in collaborations with other organizations to enhance their development capabilities. Incyte leverages its extensive intellectual property portfolio to protect and maximize the value of its therapeutic advancements in the market.
Sources:
Biocryst Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biocryst Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
